Abstract
Migraine is a painful neurological disorder that affects over 10% of the general population. Frovatriptan and rizatriptan are antimigraine agents belonging to the triptan class. Although previous studies have independently compared the efficacy of these agents, contemporaneous data examining both pharmacokinetic (PK) properties and efficacy in parallel have not previously been available.
Leibniz-HKI-Autor*innen
Identifier
doi: 10.2147/DDDT.S61295
PMID: 25092964